A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/29/2011	WO2011160798A1 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
12/29/2011	WO2011160768A1 Medical device for self-administration of patients with acute coronary events
12/29/2011	WO2011160684A1 Use of uleine for the prevention and/or the treatment of infectious diseases
12/29/2011	WO2011160632A1 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
12/29/2011	WO2011160597A1 Furocoumarin compounds with antihypertensive activity and preparation methods thereof
12/29/2011	WO2011160548A1 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and use thereof
12/29/2011	WO2011160541A1 Tolvaptan solid dispersion and its preparation method
12/29/2011	WO2011160434A1 Preparing process and quality controlling method for an compound injection
12/29/2011	WO2011160425A1 Preparing method of allicin injection and low temperature continuous stirring ultrafiltration device thereof
12/29/2011	WO2011160396A1 Method for preparation of ranolazine
12/29/2011	WO2011160268A1 Phosphoric acid ester compound of hydroxy acid substituted phenyl ester, synthesis method and medical use thereof
12/29/2011	WO2011160267A1 Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof
12/29/2011	WO2011160259A1 Use of n-carbamoyl glutamic acid, salts or esters thereof in manufacture of health care products for protecting liver or promoting muscle growth
12/29/2011	WO2011160252A1 Organic acid salts of penehyclidine optical isomer
12/29/2011	WO2011160216A2 Compounds useful in imaging and therapy
12/29/2011	WO2011160191A1 Compound for the treatment of enteroviruses
12/29/2011	WO2011160170A1 Stimulating immune response
12/29/2011	WO2011160146A1 Pharmaceutical preparation containing dextran and sodium hyaluronate for the treatment of joint disorders
12/29/2011	WO2011139414A3 Dexlansoprazole polymorphic forms
12/29/2011	WO2011137320A3 Small molecule inhibitors of usp1 deubiquitinating enzyme activity
12/29/2011	WO2011136751A3 Water soluble pharmaceutical composition
12/29/2011	WO2011135581A8 Pharmaceutical compositions of dronedarone
12/29/2011	WO2011131943A3 Pharmaceutical compositions
12/29/2011	WO2011127629A9 Pharmaceutical product of diphosphonate injection and preparation method thereof
12/29/2011	WO2011125006A3 Sultam compounds
12/29/2011	WO2011123645A3 Nucleoside phosphoramidates
12/29/2011	WO2011121452A3 Crystal forms of o-desmethylvenlafaxine fumarate
12/29/2011	WO2011120040A3 Thrombin inhibiting compositions
12/29/2011	WO2011119738A9 Methods of treatment using stem cell mobilizers
12/29/2011	WO2011119722A3 Use of anatabine to treat inflammation and methods of synthesizing anatabine
12/29/2011	WO2011113041A3 Neutralization of flt3 ligand as a leukemia therapy
12/29/2011	WO2011112840A3 Water-soluble phytosterol derivatives for reducing cholesterol and preparation thereof
12/29/2011	WO2011109767A3 Gelatinase inhibitors and prodrugs
12/29/2011	WO2011109729A9 Ep1 inhibition
12/29/2011	WO2011109367A3 Methods and compositions for treating or preventing symptoms of hormonal variations
12/29/2011	WO2011109237A9 Uses of noscapine and derivatives in subjects diagnosed with fap
12/29/2011	WO2011107866A3 Silyl-derivatives of polysaccharides
12/29/2011	WO2011103586A3 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
12/29/2011	WO2011103524A3 Cyclic tetrapeptides and therapeutic applications thereof
12/29/2011	WO2011101831A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it
12/29/2011	WO2011101829A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it
12/29/2011	WO2011101827A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent - miconazole nitrate, and a process to make it
12/29/2011	WO2011101822A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, and a corticosteroid - dexamethasone acetate, and a process to make it
12/29/2011	WO2011100550A3 Compositions and methods for treating depression
12/29/2011	WO2011097571A3 Methods for the use of progestogen as a glucocorticoid sensitizer
12/29/2011	WO2011097549A9 Treatment skin disorders
12/29/2011	WO2011097372A3 Pterostilbene cocrystals
12/29/2011	WO2011094749A3 Small molecule inhibitors that block assembly of the tgf-beta signaling complex
12/29/2011	WO2011094496A3 Trypsin-like serine protease inhibitors, and their preparation and use
12/29/2011	WO2011092663A3 Sorafenib dimethyl sulphoxide solvate
12/29/2011	WO2011091390A3 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
12/29/2011	WO2011091084A3 Stabilized proteases for use in skin care
12/29/2011	WO2011090947A3 Methods for the diagnosis and treatment of parkinson's disease
12/29/2011	WO2011090345A3 Novel antibiotic composition comprising flufenamic acid as an active ingredient
12/29/2011	WO2011090307A3 Sirna having antiviral activity against both enterovirus 70 and coxsackievirus a24, and pharmaceutical composition for treating and preventing acute hemorrhagic conjunctivitis containing same
12/29/2011	WO2011089602A3 Aloe-emodin derivatives and use thereof for the treatment of cancer
12/29/2011	WO2011089168A3 Special composition for the use thereof as a drug
12/29/2011	WO2011088474A3 Sulindac and sulindac derivatives and their uses related to infection
12/29/2011	WO2011085347A3 Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
12/29/2011	WO2011084796A3 Novel quinazoline derivatives
12/29/2011	WO2011083112A3 Solid oral dosage form containing olmesartan medoxomil
12/29/2011	WO2011071541A3 Cadherin modulatory agents
12/29/2011	WO2011048491A3 Amorphous rotigotine co-precipitates
12/29/2011	WO2011046646A3 Inhibitors of filovirus entry into host cells
12/29/2011	WO2011041634A8 Pyrazole inhibitors of phosphatidylinositol 3-kinase
12/29/2011	WO2011006596A3 Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor and corresponding methods and use
12/29/2011	WO2010132882A8 Sublingual dexmedetomidine compositions and methods of use thereof
12/29/2011	WO2010129138A3 Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
12/29/2011	WO2010108060A8 Fatty acid monoglyceride compositions
12/29/2011	WO2009153319A8 Anti-tumour compositions and methods
12/29/2011	WO2008019351A8 Compositions and their uses directed to diacylglycerol acyltransferase 1
12/29/2011	WO2001035902A3 Stabilized thyroxine compounds
12/29/2011	US20110319808 Antimicrobial composition
12/29/2011	US20110319807 Rejuvenation or preservation of germ cells
12/29/2011	US20110319805 Topical composition for treating the skin
12/29/2011	US20110319790 Pharmaceutical composition and system for permeabilizing fetal membranes
12/29/2011	US20110319625 Biphenyl compounds useful as muscarinic receptor antagonists
12/29/2011	US20110319624 Crystal form of quinoline compound and process for its production
12/29/2011	US20110319497 Ampk activator
12/29/2011	US20110319496 Process for the preparation of ajoene
12/29/2011	US20110319495 Pharmaceutical Composition for Hepatitis Treatment and Applications
12/29/2011	US20110319494 Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents
12/29/2011	US20110319493 Histone deacetylases, and uses related thereto
12/29/2011	US20110319492 Manufacture of tablets from energy-applied powder blend
12/29/2011	US20110319491 Anhydrous depigmenting compositions comprising, within the fatty phase thereof, a solubilized phenolic compound and a retinoid
12/29/2011	US20110319490 Methods and compositions for the treatment of irritable bowel syndrome
12/29/2011	US20110319489 Enhanced stability peracid compositions
12/29/2011	US20110319488 Anionic oil-in-water emulsions containing prostaglandins and uses thereof
12/29/2011	US20110319487 Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
12/29/2011	US20110319486 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same
12/29/2011	US20110319485 Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori
12/29/2011	US20110319484 Neuroprotective compounds
12/29/2011	US20110319483 1-adamantyl chalcones for the treatment of proliferative disorders
12/29/2011	US20110319482 Novel treatments
12/29/2011	US20110319481 Schweinfurthin analogues
12/29/2011	US20110319480 Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens
12/29/2011	US20110319478 Compositions to Treat Cardiac Pacing Conditions
12/29/2011	US20110319477 Mutations of the pik3ca gene in human cancers
12/29/2011	US20110319476 Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
12/29/2011	US20110319475 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

1 ... 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 ... 7860